How the Oral Mucosal Barrier Affects Peptide Delivery

The oral mucosal barrier affects peptide delivery by limiting how readily intact peptide molecules can move from a formulation, through mucus and stratified epithelium, and into underlying tissue. Peptide size, hydrophilicity, charge, membrane partitioning, epithelial organization, intercellular lipids, enzymatic degradation, saliva, and residence time can all influence this process. Buccal and other oromucosal tissues can provide direct access to underlying vasculature, but the presence of a mucosal surface does not mean that a peptide will cross it efficiently or achieve meaningful systemic exposure.

The barrier itself is therefore one of the central research questions within oromucosal peptide film research. Investigators need to separate film dissolution, peptide release, epithelial permeation, local retention, enzymatic stability, and systemic absorption rather than treating placement against the oral mucosa as proof of delivery.

Research-use notice: This article examines how the oral mucosal barrier affects peptide delivery, including epithelial permeability, mucus, intercellular lipids, peptide stability, and tissue transport. InStrips products are offered strictly for research and analytical use and are not intended to diagnose, treat, cure, or prevent any disease, absorption disorder, oral condition, peptide deficiency, digestive disorder, injury, or other medical condition.

Contact between a peptide formulation and the oral mucosa does not establish absorption, bioavailability, systemic exposure, therapeutic effectiveness, appropriate administration, or suitability for any person.

The Oral Mucosa Is a Biological Barrier, Not an Open Membrane

The oral cavity contains several mucosal surfaces with different structural properties.

Relevant regions can include:

• buccal mucosa
• sublingual mucosa
• gingival mucosa
• palatal mucosa

These tissues should not be treated as equally permeable.

Buccal and Sublingual Mucosa Are Structurally Different

The buccal mucosa lines the inner cheek, while the sublingual mucosa is located beneath the tongue.

Differences can include:

• epithelial thickness
• degree of keratinization
• vascular environment
• salivary exposure
• mechanical movement

A permeability result from one oral site should therefore not automatically be generalized to another.

Buccal Epithelium Is Stratified

Buccal mucosa contains multiple epithelial cell layers rather than a single-cell membrane.

A molecule moving from the oral cavity toward underlying tissue must therefore cross a relatively complex epithelial structure.

This is especially relevant for large hydrophilic molecules such as many peptides.

Non-Keratinized Does Not Mean Highly Permeable to Every Molecule

Buccal mucosa is generally described as non-keratinized and more permeable than strongly keratinized oral tissues.

However, relative permeability does not eliminate barriers arising from:

• molecular size
• hydrophilicity
• charge
• intercellular lipids
• enzymatic degradation

The Superficial Epithelium Provides an Important Permeability Barrier

Research on oral peptide transport has emphasized the importance of the superficial epithelial layers.

Organized intercellular lipids can restrict movement of hydrophilic macromolecules between epithelial cells.

Intercellular Lipids Matter

The spaces between epithelial cells are not simply water-filled channels.

They contain structured lipid-associated material that can limit diffusion.

This is one reason peptide transport across buccal tissue can remain low even when the tissue is well vascularized beneath the epithelium.

Vascular Supply Does Not Remove the Epithelial Barrier

Buccal mucosa has a substantial blood supply.

That can be relevant once a molecule reaches the underlying tissue.

But the molecule must first cross the epithelial barrier.

Good vascularization therefore does not establish good peptide permeability.

Delivery Involves Several Sequential Steps

A film-associated peptide may need to:

• be released from the formulation
• dissolve in the local aqueous environment
• remain chemically intact
• remain near the mucosal surface
• partition into or around epithelial cells
• cross the tissue
• reach underlying circulation if systemic exposure is the objective

Failure at any stage can reduce overall delivery.

Film Release Is Not Mucosal Permeation

A laboratory dissolution study may show that peptide leaves a film rapidly.

This establishes formulation release under the tested conditions.

It does not establish that the released peptide crosses mucosa.

Mucosal Contact Is Not Absorption

A mucoadhesive formulation may remain attached to tissue for an extended period.

This can increase opportunity for interaction with the mucosa.

Residence time still does not establish:

• permeation rate
• fraction absorbed
• systemic bioavailability

The Mucus Layer Adds Another Interface

Before reaching epithelial membranes, a peptide may encounter mucus and other salivary components.

Mucus can influence:

• diffusion
• retention
• hydration
• binding

Mucus Can Both Retain and Hinder Molecules

A mucoadhesive formulation may benefit from interaction with mucus.

At the same time, strong molecular interactions with mucin can slow diffusion of the released peptide toward the epithelium.

Retention and transport are therefore not always aligned.

Hydration Changes the Barrier Environment

Oral films commonly absorb water after contact with saliva.

Hydration can affect:

• polymer swelling
• peptide release
• film adhesion
• diffusion

More rapid hydration does not automatically produce greater transmucosal transport.

Saliva Creates a Moving Aqueous Environment

Saliva can:

• dissolve formulation components
• dilute released peptide
• move material away from the application site
• contribute enzymes

This makes the oromucosal surface different from a static laboratory membrane.

Washout Competes With Permeation

Once a peptide leaves the film, several outcomes are possible.

It may:

• remain near the mucosa
• diffuse toward epithelial tissue
• be diluted in saliva
• be swallowed

The relative rates of these processes influence exposure at the mucosal surface.

Peptide Size Can Strongly Limit Passive Diffusion

Many peptides are substantially larger than conventional small-molecule drugs.

Increasing molecular size generally makes passive movement through restrictive epithelial pathways more difficult.

Hydrophilicity Creates a Different Problem

Peptides commonly contain polar and ionizable groups.

This can make them readily soluble in aqueous environments while reducing their ability to partition through lipid-associated regions of biological membranes.

Solubility and Permeability Can Pull in Opposite Directions

A molecule may dissolve very well in saliva but cross epithelial barriers poorly.

Conversely, increasing lipophilicity can create other formulation or solubility problems.

Successful delivery therefore cannot be predicted from one physicochemical property.

Charge Matters Too

Peptide charge depends on:

• amino-acid sequence
• terminal groups
• local pH

Charge can influence interactions with:

• mucus
• cell surfaces
• membrane lipids
• other formulation components

Local pH Can Change Peptide Ionization

Peptides often contain several ionizable residues.

A change in microenvironmental pH can alter:

• net charge
• solubility
• membrane interaction
• stability

This is one reason formulation pH can matter in permeability experiments.

Peptides May Use More Than One Transport Pathway

Possible routes across oral epithelium include:

• intercellular transport between cells
• transcellular transport through cells
• specialized transport mechanisms in selected cases

For many peptides, passive transport is thought to be important and intercellular movement can contribute substantially.

Intercellular Transport Has Its Own Barrier

Moving between cells still requires navigating structured extracellular and lipid-associated regions.

The intercellular pathway should not be imagined as an unrestricted aqueous pore.

Transcellular Transport Requires Membrane Crossing

A transcellular route may require a molecule to cross:

• apical cell membrane
• intracellular environment
• basolateral membrane

For a large hydrophilic peptide, this can be energetically unfavorable without additional mechanisms.

Transport Pathways Can Be Studied Experimentally

Researchers can use:

• ex-vivo tissue
• diffusion chambers
• fluorescent tracers
• histological imaging
• permeability markers

to investigate how molecules cross mucosal tissue.

Franz Diffusion Cells Are One Common Experimental System

Excised mucosal tissue can be mounted between donor and receiver compartments.

Researchers may place a formulation or peptide solution on the donor side and measure material appearing in the receiver compartment over time.

Flux Can Be Calculated

Researchers may calculate transport as:

• cumulative amount permeated
• flux per unit tissue area
• apparent permeability coefficient

These values provide quantitative information about tissue transport under the experimental conditions.

Permeability Coefficient Is Not Human Bioavailability

An ex-vivo permeability coefficient does not include:

• salivary clearance
• swallowing
• blood flow
• whole-body distribution
• systemic clearance

It should therefore not be converted directly into human systemic exposure.

Tissue Source Can Change the Result

Buccal permeability experiments may use:

• human tissue
• porcine tissue
• other animal mucosa

Species differ in epithelial thickness, lipid composition, and other structural properties.

Porcine Buccal Mucosa Is Often Used as a Model

Pig buccal tissue has frequently been used because its structural characteristics can provide a useful experimental approximation of human buccal mucosa.

Similarity does not mean quantitative equivalence.

Tissue Viability Matters

Excised tissue can change after removal.

Researchers need to consider:

• storage
• temperature
• time after collection
• physical damage

Compromised tissue can appear artificially permeable.

Barrier Integrity Can Be Tested

Investigators may use marker compounds or electrical measurements to determine whether the tissue remains intact during an experiment.

A large permeability increase is difficult to interpret if the tissue barrier has been damaged.

Enhancers Can Increase Permeability by Changing the Barrier

Permeation-enhancing formulations may alter:

• membrane lipids
• protein organization
• intercellular pathways
• mucus properties

The mechanism and reversibility of the change matter.

Greater Permeability Is Not Automatically Desirable

A formulation that disrupts tissue strongly may increase experimental flux while also compromising epithelial integrity.

Permeation and tissue compatibility therefore need separate evaluation.

Barrier Recovery Can Be Studied

Researchers may examine whether permeability or electrical resistance returns toward baseline after an enhancer is removed.

This can provide information about whether the barrier change is temporary or persistent.

Histology Can Reveal Structural Damage

Microscopic examination can show:

• epithelial disruption
• cell separation
• surface damage
• tissue swelling

A transport result is more informative when tissue structure is evaluated alongside it.

Enzymatic Degradation Adds a Biochemical Barrier

Peptides can be degraded before or during transport by:

• salivary enzymes
• mucosal peptidases
• intracellular enzymes

This means a low receiver-compartment signal could reflect degradation as well as poor permeability.

Intact Peptide and Total Peptide-Derived Material Are Different

An analytical assay should ideally distinguish:

• intact peptide
• fragments
• other degradation products

Detecting peptide-derived material does not necessarily establish intact peptide transport.

Mass Spectrometry Can Help Confirm Molecular Identity

Chromatographic and mass-spectrometric methods can be used to determine whether material appearing across a tissue retains the expected molecular identity.

This is especially important for peptides that may undergo rapid cleavage.

Formulation Stability Is Another Separate Issue

A peptide may degrade inside the film before reaching the mucosa.

Researchers therefore need to distinguish:

• storage stability
• release stability
• mucosal stability
• post-absorption stability

Mucoadhesion Can Increase Contact Opportunity

Mucoadhesive polymers are investigated because they can keep a formulation near the intended mucosal region for longer.

This may reduce immediate displacement.

It does not guarantee greater peptide flux.

Very Strong Adhesion Can Introduce Other Problems

Excessive adhesion or swelling can influence:

• comfort
• film hydration
• release rate
• local diffusion

Residence time needs to be balanced with release and tissue interaction.

Film Thickness Can Influence Release

A thicker film may:

• contain more polymer
• hydrate more slowly
• extend diffusion distance
• change mechanical behavior

Film thickness and mucosal permeability are separate variables.

Peptide Loading Does Not Predict Fraction Absorbed

Increasing the amount of peptide in a film can increase the concentration available at the tissue surface.

However, the barrier may remain rate-limiting.

More material loaded does not establish proportionally greater absorption.

Concentration Gradient Can Influence Passive Diffusion

Passive diffusion is partly driven by concentration differences across the tissue.

A larger donor-side concentration can increase driving force under some conditions.

But this relationship may become limited by:

• solubility
• saturation
• degradation
• tissue barrier properties

Sink Conditions Matter in Laboratory Experiments

Receiver compartments are often designed to maintain low peptide concentration so that diffusion continues toward the receiver side.

This can create a stronger and more consistent concentration gradient than occurs in vivo.

Laboratory Conditions Can Therefore Overestimate Practical Transport

An optimized diffusion-cell experiment may remove several real-world limitations, including:

• salivary washout
• swallowing
• variable movement

Translation requires additional evidence.

Buccal Delivery and Gastrointestinal Oral Delivery Are Different

An oromucosal formulation is designed to interact with oral mucosa before swallowing.

A conventional swallowed oral peptide must additionally encounter:

• gastric conditions
• intestinal enzymes
• intestinal epithelium
• first-pass processes

The two delivery routes should not be discussed interchangeably.

Avoiding Gastrointestinal Exposure Does Not Eliminate All Barriers

Oromucosal research can bypass some gastrointestinal limitations.

It still faces:

• oral mucosal permeability
• salivary dilution
• peptidases
• short residence time

Primary Barrier Reviews Emphasize Peptide-Specific Limitations

Research reviews of buccal peptide transport consistently emphasize molecular size, hydrophilicity, low membrane permeability, enzymatic degradation, and formulation contact time as major variables. A foundational review is available through PubMed.

Peptide Physicochemical Properties Provide the Next Question

The barrier cannot be understood independently of the molecule trying to cross it.

The roles of molecular size, polarity, charge, and aqueous affinity are examined in why peptide size and hydrophilicity matter in oromucosal transport.

What Oral Mucosal Barrier Research Does Not Establish

Barrier research does not by itself establish:

• successful delivery of a specific peptide
• high systemic bioavailability
• equivalence to another route
• clinical effectiveness
• an appropriate amount for human use
• suitability for any person

Final Perspective

The oral mucosal barrier affects peptide delivery through a combination of epithelial structure, intercellular lipids, mucus, saliva, physicochemical constraints, enzyme activity, and formulation residence time.

Oromucosal contact can create an opportunity for peptide transport, but it does not remove the biological barriers separating a film from underlying tissue or systemic circulation.

Accurate interpretation should therefore distinguish film release from mucosal permeation, mucosal permeation from absorption, and experimental permeability from demonstrated systemic bioavailability or clinical effect.